Tag: Aimmune Therapeutics

Palforzia Capsules with Logo

Aimmune Warns Coronavirus Will Slow Marketing of Palforzia Treatment for Peanut...

The company warned that it has had to postpone in-person workshops to train physicians.
Palforzia Capsules with Logo

Aimmune Provides FDA Mandated Program for Patients Considering Treatment of Peanut...

The FDA seeks to mitigate risks associated with treatment by mandating a program that must be followed by patients, prescribers, pharmacies, and healthcare settings.
Aimmune + Xencor

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...

“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
Palforzia

FDA Approves Aimmune’s PALFORZIA as First Treatment for Peanut Allergy

Palforzia is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
Paliforzia (AR101)

FAQ for Palforzia, the First FDA Approved Therapy for Food Allergy

What it is, what it treats, who it is for, how it is used, et al.
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
AR101

FDA to Hold Open Advisory Meeting on AR101 Peanut Allergy OIT...

CBER will provide a live webcast of the committee meeting free of charge.
FARE Reponse to ICER Report

Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies

FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
AAFA Reponse to ICER Report

Asthma and Allergy Foundation of America Responds to Premature ICER Review...

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
Aimmune Reponse to ICER Report

Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final...

Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community.